Analyst Price Targets — NYXH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 10, 2026 11:43 am | Jonathan Block | Stifel Nicolaus | $8.00 | $2.90 | TheFly | Nyxoah price target lowered to $8 from $10 at Stifel |
| January 29, 2026 1:34 pm | Jonathan Block | Stifel Nicolaus | $11.00 | $4.83 | TheFly | Nyxoah price target lowered to $11 from $12 at Stifel |
| November 14, 2025 1:12 pm | Adam Maeder | Piper Sandler | $9.00 | $4.84 | StreetInsider | Nyxoah SA (NYXH) PT Lowered to $9 at Piper Sandler |
| October 14, 2024 6:45 am | Edward White | H.C. Wainwright | $17.00 | $9.60 | StreetInsider | Nyxoah SA (NYXH) PT Lowered to $17 at H.C. Wainwright |
| May 24, 2024 6:06 am | Edward White | H.C. Wainwright | $18.00 | $8.33 | TheFly | Nyxoah price target lowered to $18 from $22 at H.C. Wainwright |
| May 15, 2024 6:35 am | Ross Osborn | Cantor Fitzgerald | $17.00 | $9.58 | StreetInsider | Nyxoah SA (NYXH) PT Lowered to $17 at Cantor Fitzgerald |
| May 15, 2024 6:03 am | Suraj Kalia | Oppenheimer | $15.00 | $9.58 | StreetInsider | Nyxoah SA (NYXH) PT Lowered to $15 at Oppenheimer |
| March 20, 2024 4:37 am | Jonathan Block | Stifel Nicolaus | $27.00 | $13.90 | StreetInsider | Nyxoah SA (NYXH) PT Raised to $27 at Stifel |
| March 14, 2024 6:35 am | Suraj Kalia | Oppenheimer | $20.00 | $16.58 | StreetInsider | Nyxoah SA (NYXH) PT Raised to $20 at Oppenheimer |
| May 6, 2022 12:00 am | Suraj Kalia | Oppenheimer | $30.00 | $14.72 | TipRanks Contributor | 2 ‘Strong Buy’ Stocks Oppenheimer Sees Surging Over 80% |
Latest News for NYXH
Nyxoah (NASDAQ: NYXH - Get Free Report) and Omnicell (NASDAQ: OMCL - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, profitability, risk, institutional ownership and valuation. Volatility and Risk Nyxoah has a beta of 1.56,
Rennova Health (OTCMKTS:RNVA - Get Free Report) and Nyxoah (NASDAQ: NYXH - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings. Volatility and Risk Rennova Health has a beta
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), March 20, 2026 , 10:30 pm CET / 5:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. Robert Taub / Robelga SRL On March 19, 2026, Nyxoah…
Nyxoah SA (NYXH) Q4 2025 Earnings Call Transcript
Nyxoah SA (NYXH) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.49 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for NYXH.
Senate Trading
No Senate trades found for NYXH.
U.S. House Trading
No House trades found for NYXH.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.